PanOptica Takes $30MM Series A Round, Licenses Ophthalmic Drug From Astellas
This article was originally published in The Pink Sheet Daily
Executive Summary
Seeking an easy-to-administer eye drop to treat AMD, the New Jersey startup drew on existing connections for a big first round.